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OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN THIRD COMPLETE
REMISSION (CR3): A VITAL ROLE FOR GRAFT-VERSUS-HOST-DISEASE/
GRAFT-VERSUS-LEUKEMIA EFFECT IN SURVIVAL
Gassas, A.1, Ishaqi, M.K.1, Afzal, S.1, John, D.J.1 1Hospital for Sick
Children, Toronto, ON, Canada.
Children with acute lymphoblastic leukemia (ALL) who suffer
2 relapses could be salvaged by hematopoietic stem cell trans-
plantation (HSCT) provided they respond to the pre HSCT
chemotherapy and enter remission. However, these patients are
at very high risk for post HSCT relapse and also at a high risk
for transplant related mortality (TRM). Our objective, herein,
was to review the outcome of children (0-18years) with ALL
who received allogeneic HSCT in third complete remission
(CR3) at our institution. From January 1994 – August 2005,
twenty-two consecutive children in CR3 received HSCT in our
instituation. Conditioning regimens included single dose VP16
(60mg/kg IV over 4 hours) and fractionated total body irradia-
tion (TBI; 1200cGy) in six fractions over 3 days (VP16/TBI) in
10 patients and cyclophosphamide 50mg/kg IV over 1 hour daily
for 4 days followed by the same dose of TBI (CY/TBI) in 12
patients. Almost all children received cyclosporine A and a short
course of methotrexate for graft-versus-host disease (GVHD)
prophylaxis, and all patients were in complete morphological
remission prior to HSCT. Median age was 8.4 years (range
3-15.4). Donor sources were as follows: matched sibling donor
(MSD), 8; matched unrelated donor (MUD) 6; one antigen
mismatch related donor (MMRD) 4; one antigen mismatched
unrelated donor (MMUD) 3 and one patient received 1 antigen
mismatched cord progenitor stem cells. White cell engraftment
was successful at a median of 18 days (range 9-29). Ten patients
died of TRM, seven relapsed, one died from other causes and
four patients are long term survivors at a median follow up of
3.7 years (range 1-10.2). All patients who did not develop
clinical acute or chronic GVHD relapsed and died. Event free
survival was (EFS 19%  4%). Three out of the 4 survivors
received MMUD and all 4 survivors had moderate to severe
acute GVHD and three had chronic GVHD, limited in two and
extensive in one. Conclusion: Children with ALL in CR3
receiving HSCT are extremely high risk for relapse and trans-
plant related mortality. These children have already relapsed
twice and demonstrated chemotherapy resistance and GVL/
GVHD plays a key role in leukemia eradication. Although,
TRM is high in such patients and GVHD could potentially
increase TRM, there are no survivors without GVHD and
exploring means of inducing GVHD by reduction of immuno-
suppressive medications or other means of immunotherapy
should be considered in these patients.
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OUTCOME OF MATCHED SIBLING DONOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR STANDARD RISK PEDIATRIC ACUTE MYELOG-
ENOUS LEUKEMIA IN FIRST COMPLETE REMISSION
Gassas, A.1, Afzal, S.1, Ishaqi, M.K.1, Doyle, J.1 1Hospital for Sick
Children, Toronto, ON, Canada.
In recent years there has been a signiﬁcant improvement in the
outcome of children with standard risk acute myelogenous leu-
kemia (AML) treated with chemotherapy only. In the MRC-UK
trials 10 and 12, standard risk AML children were allowed to
proceed to hematopoietic stem cell transplantation (HSCT) if
there is a full matched family donor. However, with the excel-
lent results of chemotherapy and the known risks and long term
effects of HSCT, this decision remains controversial. Herein,
our objective was to review the outcome of all children between
1995-2005 with standard risk AML who received a matched
sibling donor (MSD) in CR1 in our institution and compare
their outcome with the published MRC-UK results. Standard
risk features were deﬁned according to the MRC-UK criteria.
Thirty-two consecutive children (16 males:16 females) received
MSD HSCT between 1995-2005 at the Hospital for Sick Chil-
dren, Toronto. Median age was 8.4 years (range 0.5-17.5 years).
Conditioning regimens included; busulphan/cyclophosphamide
(Bu/Cy) n23; Cy/Total body irradiation (TBI) n4, VP16/
TBI n4 and Bu/Melphalan (Bu/Mel) n1. Graft-versus-host
disease (GVHD) prophylaxis was with cyclosporine A and a
short course of methotrexate. All patients engrafted apart from
one patient who was conditioned with VP16/TBI and suffered a
primary graft failure. That patient was re-conditioned with
Bu/Cy/ATG and successfully engraft and still alive 6 years post
the second HSCT. Acute grade I-II and grade III-IV GVHD
occurred in 6 and 1 patients, respectively. Chronic GVHD
affected 3 patients, limited in 2 and extensive in 1. One patient
died from transplant related mortality (TRM). Eight patients
relapsed and six died from their disease. Two relapsed patients
received a second HSCT and continue to be in remission for 8
and 55 months, respectively. For a median follow up of 52
months (range 6-104 months), the relapse free survival (RFS) is
75% and the event free survival (EFS) including the 2 patients
who received the second HSCT is 81%. Larger studies such as
the MRC-UK 10 and 12 reported 63% RFS. Conclusion:
Outcome of children with standard risk AML transplanted from
a MSD in CR1 is very encouraging with minimal toxicity.
HSCT for standard risk patient with an available family donor
should be recommended.
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PEDIATRIC PATIENTS WITH MALIGNANCIES TRANSPLANTED WITH
PLASMA DEPLETED CORD BLOOD (PD CB) – AN AUDITED ANALYSIS OF
91 PATIENTS
Graham, M.1, Chan, L.L.2, Eames, G.3, Tan, A.M.4, Tan, P.L.5,
Rosenthal, J.6, Nademanee, A.6, Karanes, C.6, Gjertson, D.7,
Wang, B.8, Petz, L.8, Chow, R.8,9,10 1University of Arizona Medical
Center, Tucson, AZ; 2University of Malaya Medical Center, Kuala
Lumpar, Malaysia; 3Cook Children’s Medical Center, Fort Worth, TX;
4KK Women & Children’s Hospital, Singapore; 5National University
Hospital, Singapore; 6City of Hope Medical Center, Duarte, CA;
7UCLA School of Public Health, Los Angeles, CA; 8StemCyte Interna-
tional Cord Blood Center, Arcadia, CA; 9StemCyte Taiwan National
Cord Blood Center, Linkou, Taiwan; 10StemCyte Research Institute,
Arcadia, CA.
Cell dosage has a critical effect on cord blood transplantation
(CBT) outcome; therefore pediatric patients are ideal for CBT.
Younger recipient age is associated with better survival and
neutrophil (ANC500) engraftment. However, even in young
patients, outcome may be improved by increasing cell dose of
the transplanted CB. CB banks practice red cell depletion
(RCD) techniques to save storage space, which incur signiﬁcant
nucleated cell loss after processing; therefore, one method to
minimize cell loss and still reduce volume after processing is to
deplete plasma (PD), but not the red blood cells. Not washing
UCB (NW) after thawing also minimizes cell loss. A large
racially diverse PD UCB inventory of over 25,000 units is now
available. There were 39 ALL, 23 AML, 5 JMML, 4 CML, and
20 other pediatric patients transplanted for malignant indica-
tions. Patients were classiﬁed as pediatric in two different ways:
by age (less than 16 years) and by weight (less than 50kg). If the
age deﬁnition is used, there were 88 pediatric patients trans-
planted with 89 PD UCB units (8 double cords); and if classiﬁed
by weight, there were 78 patients transplanted with 78 PD UCB
units (4 double cords). A retrospective audited analysis was
performed on all 91 pediatric patients with engraftment and/or
survival information. Of these, 24 patients had standard risks
(26%), 58 patients (64%) with advanced risks and 9 risk status
unknown (10%). The median age of combined patients was 5.8
years old (range 0.5-34); median weight 22 kg (range 5-91.6);
male 66%. Transplant characteristics indicated a median # HLA
ABDR matches of 5.0; median pre-freeze TNC dose 6.1 
107/kg; median post-thaw TNC dose as reported by TC 5.5 
107/kg; median pre-freeze CD34 dose 2.0  105/kg; transplants
outside of U.S. 25%; double unit transplant 10%; non-myeloa-
blative 9%. 56.5% of the transplanted UCB were washed post-
thaw (W), 33.7% were infused without post-thaw wash (NW),
with 9.8% of the units without available post-thaw data. Median
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follow-up time was 175.5 days (range 19-1402 days). Kaplan-
Meier estimates were used for engraftment, relapse, TRM, OS
and RFS rates with all patients who expired before engraftment
counted as engraftment failures. Patients were also stratiﬁed by
risk status. Results are summarized below. These results dem-
onstrate that HSCT using unrelated PD UCB can be performed
safely with outstanding results in pediatric patients with malig-
nancies.
Outcome Summary
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SUPERIOR DISEASE-FREE SURVIVAL IN ACUTE MYELOGENOUS LEUKE-
MIA/MYELODYSPLASTIC SYNDROME RECEIVING REDUCED-INTENSITY
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM
UNRELATED DONORS USING FLUDARABINE, BUSULFAN, AND TOTAL
LYMPHOID IRRADIATION
Kato, K.1, Khaled, Y.1, Braun, T.2, Levine, J.E.1, Ferrara, J.L.M.1,
Mineishi, S.1, Gregory, Y.A.1 1Blood and Marrow Stem Cell Trans-
plantation Program, University of Michigan, Ann Arbor, MI; 2Depart-
ment of Biostatistics, School of Public Health, University of Michigan,
Ann Arbor, MI.
Reduced-intensity stem cell transplantation (RIST) from un-
related donors (UD) is shown to be feasible treatment option for
acute myelogenous leukemia/myelodysplastic syndrome (AML/
MDS). Although morbidity and mortality from graft-versus-
host disease (GVHD) may be still signiﬁcant, transplant from
UD may carry more potent graft-versus-leukemia (GVL) effect.
Patients and Method A total of 36 patients (median age: 59
years old, range: 2-69) with AML/MDS were transplanted with
RIST using related and unrelated donors. Patients were condi-
tioned with ﬂudarabine (125mg/m2), intravenous busulfan
(6.4mg/kg), and total lymphoid irradiation (2-4Gy) (Flu/Bu/
TLI). Tacrolimus and methotrexate were given as prophylaxis
for GVHD. Twenty patients underwent RIST in complete
remission (CR), and remaining 16 patients in non-CR. Related
donors (RD) were used in 16 patients (8 in CR and 8 in non-CR
at transplantation), and UD in 20 patients (12 were in CR and
8 in non-CR at transplantation).
Results The median follow-up of survivors was 971 days
(range: 109-1489), while 14 patients relapsed between 16 and
794 days (median 181 days). Overall survival (OS) and disease-
free survival (DFS) at 2 years after RIST were 29.5% and
28.5%, repsectively. The incidence of acute GVHD was rela-
tively low (grade 0: 58%, grade 1: 19%, grade 2: 14%: grade 3-4:
8%). A survival advantage was seen for UD compared to RD
(DFS at 2 years: 42.0% versus 9.2%, log-rank P0.009). The
relapse rate after RIST from RD was 71%, while from UD was
23%. The following factors were analyzed by univariate and
multivariate analyses: age, sex, disease status at transplantation,
source of stem cells (peripheral blood or bone marrow), RD or
UD, number of CD34 positive cells transplanted, and acute
GVHD. In univariate analysis, RD, non-CR at transplant, and
low cell doses transplanted (less than 5  106 /kg of CD34
positive cells), were identiﬁed as poor prognostic factors for
DFS. In multivariate analysis, RD (P0.029), non-CR at trans-
plantation (P0.020), and low cell doses (P0.030) were iden-
tiﬁed as independent risk factors for DFS. Complete donor
chimerism was achieved more consistently by day 100 in trans-
plants from UD than from RD (P0.044).
Conclusion Our observations suggest that RIST using
Flu/Bu/TLI from UD is a feasible transplant option for AML/
MDS patients, with possibly more potent GVL effect than using
RD through early achievement of complete donor chimerism.
Unrelated versus related donors in RIST for AML/MDS
Stem cell source
Acute
GVHD
(grade2-4)
NRM
at 2yr
relapse
at 2yr
2yr
DFS
Unrelated donors
(UD) 25% 32% 23% 42%
Related donors
(RD) 19% 32% 71% 9%
NRM indicates non relapse mortality. NRM and relapse rate are
evaluated by the cumulative incidence using Gray’s method.
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SUPERIOR EFS AND REDUCED TRM IN PATIENTS WITH INT-2 AND
HIGH RISK MDS AND SECONDARY AML AFTER INITIAL CYTOREDUC-
TION WITH 5-AZACYTIDINE
McCarty, J.M.1, Roberts, C.H.1, Candler, K.S.1, Edwards, R.W.1,
Chung, H.M.1, Shickle, L.M.1 1BMT Program, Massey Cancer Center,
VCU Medical Center, Richmond, VA.
Optimized preparative regimens and supportive care have al-
lowed more MDS patients access to potentially curative stem cell
transplantation. Early relapse accounts for up to 30% of advanced
MDS. Leukemia induction chemotherapy prior to transplant re-
duces relapse incidence but with increased TRM. 5-Azacytidine
(5Aza) in advanced MDS may delay disease progression to AML,
has a signiﬁcant response, reduces marrow blast counts, often
within the ﬁrst 2-4 cycles, and is well tolerated. We examined the
use of pre-transplant cytoreduction with 5Aza in Int-2 or High risk
MDS and secondary AML. Patients received at least 4 cycles of
5Aza. Patients with improving marrow blast counts continued on
5Aza to best response(n10), those with greater than 20% blasts
were treated with FLAG(n7), and 5Aza patients with progressive
blast counts crossed over to FLAG(n5). Patients achieving CR/
VGPR proceeded to transplant. 22 patients (median age 49 range
16-68) were followed from the initiation of treatment. With a
median follow up of 535 days (range 36 to 1435), EFS of both 5Aza
and FLAG treated patients was comparable (MS not yet reached)
in contrast to shorter EFS of 5Aza patients crossing over to FLAG
(MS 18 mo). Tests of equality over groups are not signiﬁcant
(Log-Rank p0.1652), although data suggests better early EFS in
the 5Aza alone group. Of the initial 22 patients, 17 underwent
allogeneic transplant (median age 46, range 16-62). The remainder
were ineligible due to refractory disease, infection or comorbidi-
ties. Patients received targeted busulfan-based preparative regi-
mens; 9 received MRD and 8 MUD transplant. With median
follow up of 250 days(range 24-1304), EFS of the 5Aza group is
superior to the FLAG group (MS not yet reached); both are far
superior to the 5Aza to FLAG group(MS 7 mo; Log-Rank
p0.0448). All patients receiving chemotherapy had a higher rate
of early TRM compared with those receiving 5Aza alone. It is
unclear if the inferior EFS of the 5Aza to FLAG group is due to
higher TRM or identiﬁes patients at higher risk for early relapse.
While these cohorts are small, they represent the longest continu-
ing follow up of patients treated with this strategy, and their
survival compares very favorably with historical EFS for MDS.
These early results suggest 5Aza as initial cytoreductive therapy
before transplantation is a strategy worth pursuing in planned
larger multicenter trials to conﬁrm these promising outcomes.
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ADULT PATIENTS WITH MALIGNANCIES TRANSPLANTED WITH
PLASMA DEPLETED CORD BLOOD (PD CB) – A RETROSPECTIVE AU-
DITED ANALYSIS OF 68 PATIENTS
Nademanee, A.1, Graham, M.2, Ballen, K.3, Tan, A.M.4,
Rosenthal, J.1, Karanes, C.1, Eames, G.5, Tan, P.6, Jaing, T.-H.7,
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